Tuesday 16th August 2022

ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) |

[ad_1]

ITEM 7.01 REGULATION FD DISCLOSURE

On October 26, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release
announcing that management will host a conference call and webcast to provide
details related to the launch of its Phase 3 first-line gastroesophageal
adenocarcinoma (GEA) pivotal study, HERIZON-GEA-01, and to discuss the
commercial potential of zanidatamab in gastrointestinal cancers.

On October 26, 2021, Zymeworks filed this press release with the Canadian
securities regulatory authorities on the System for Electronic Document Analysis
and Retrieval (“SEDAR”) at www.sedar.com. A copy of this press release is
attached as Exhibit 99.1 hereto.

The information provided under this Item (including Exhibit 99.1, attached
hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS


(d) Exhibits



Exhibit No.       Description

99.1                Press Release dated October 26, 2021.

104               Cover Page Interactive Data File (embedded as Inline XBRL document).

——————————————————————————–

© Edgar Online, source Glimpses

[ad_2]

Read More:ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) |